This Phase Ib trial is evaluating how safe a targeted therapy (lemzoparlimab) is when used with other cancer treatments (azacitidine and/or venetoclax) in people with acute myeloid leukaemia or myelodysplastic syndrome..
This trial is treating patients with acute myeloid leukaemia and myelodysplastic syndrome.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination With Venetoclax and/or Azacitidine in Subjects With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This is a non-randomised trial with five experimental arms that is evaluating lemzoparlimab in combination with azacitidine and venetoclax for the treatment of acute myeloid leukaemia (AML) and with azacitidine with or without venetoclax for the treatment of myelodysplastic syndrome (MDS). Participants will receive lemzoparlimab intravenously once weekly (Q1W), venetoclax oral tablets once daily (QD) for 28 days (AML participants) or 14 days (MDS participants), and azacitidine by subcutaneous injection or intravenously QD for 7 days of each 28-day cycle.
Not Recruiting Hospitals Read More